Drug Trial Radar · NCT02928224
Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Dec 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
702
Actual
Start
Oct 13, 2016
Primary completion
Feb 11, 2019
Study completion Nov 10, 2022
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany; Pierre Fabre Medicament; Ono Pharmaceutical Co., Ltd.
- First posted
- Oct 10, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, open-label, 3-arm Phase 3 study to evaluate encorafenib + cetuximab plus or minus binimetinib versus Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab, as controls, in patients with BRAFV600E mCRC whose disease has progressed after 1 or 2 prior regimens in the metastatic setting. The study contains a Safety Lead-in Phase in which the safety and tolerability of encorafenib + binimetinib + cetuximab will be assessed prior to the Phase 3 portion of the study.
Conditions
- BRAF V600E-mutant Metastatic Colorectal Cancer
Interventions
EncorafenibDrug
Orally, once daily.
BinimetinibDrug
Orally, twice daily.
CetuximabDrug
Standard of care.
IrinotecanDrug
Standard of care.
Folinic AcidDrug
Standard of care.
5-FluorouracilDrug
Standard of care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- (Safety Lead-in) Number of Participants With Dose-Limiting Toxicities (DLTs)Time frame: Cycle 1 (up to 28 days)
- (Safety Lead-in) Number of Participants With Adverse Events (AEs)Time frame: Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)
- (Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs) - Interim AnalysisTime frame: Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)
- (Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs) - Final AnalysisTime frame: From start of study treatment until 30 days post last dose of study treatment (maximum treatment exposure of 280 weeks)
- (Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm - Interim AnalysisTime frame: From randomization to death due to any cause until 204 deaths were observed (maximum treatment exposure of 89.1 weeks for triplet arm and 52.4 weeks for control arm)
- (Phase 3) Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors (RECIST), v1.1 of Triplet Arm vs. Control ArmTime frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle)
Locations
418 sites in 27 countries. Site status is shown where the registry gives one.
Mayo Clinic Hospital
Phoenix, Arizona
Mayo Clinic
Phoenix, Arizona
Mayo Clinic
Scottsdale, Arizona
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, California
Compassionate Care Research Group, Inc. at Compassionate Cancer Care Medical Group, Inc.
Fountain Valley, California
Keck Hospital of USC - Norris Healthcare Center (HC3)
Los Angeles, California
Keck Hospital of USC
Los Angeles, California
LAC+USC Medical Center
Los Angeles, California
Norris Healthcare Center 3 (HC3)
Los Angeles, California
USC Eye Institute
Los Angeles, California
USC/Norris Comprehensive Cancer Center
Los Angeles, California
Hoag Memorial Hospital Presbyterian
Newport Beach, California
Harvard Eye Associates
Orange, California
Rocky Mountain Lions Eye Institute
Aurora, Colorado
University of Colorado Cancer Center - Anschutz Cancer Pavilion
Aurora, Colorado
University of Colorado Denver CTO (CTRC)
Aurora, Colorado
University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)
Aurora, Colorado
University of Colorado Hospital Inpatient Pavillion'
Aurora, Colorado
Smilow Cancer Hospital at Yale - New Haven
New Haven, Connecticut
Temple Medical Center
New Haven, Connecticut
Yale University, Yale Cancer Center
New Haven, Connecticut
Smilow Cancer Hospital Care Center at North Haven
North Haven, Connecticut
The Lennar Foundation Medical Center
Coral Gables, Florida
Broward Health Medical Center
Fort Lauderdale, Florida
Dr. Clayton Berger (opthalmology)
Fort Lauderdale, Florida
Mehmet F. Hepgur, MD - Broward Health Medical Center
Fort Lauderdale, Florida
Mayo Clinic Florida
Jacksonville, Florida
Sylvester Comprehensive Cancer Center/UMHC
Miami, Florida
Sylvester at Kendall
Miami, Florida
Illinois CancerCare- Bloomington
Bloomington, Illinois
University of Chicago Medical Center
Chicago, Illinois
Illinois CancerCare- Galesburg
Galesburg, Illinois
University of Chicago Comprehensive Cancer Center at Silver Cross Hospital
New Lenox, Illinois
The University of Chicago Medicine Center for Advanced Care Orland Park
Orland Park, Illinois
Illinois CancerCare- Ottawa
Ottawa, Illinois
Illinois Cancer Care, PC
Peoria, Illinois
Illinois Eye Center
Peoria, Illinois
Carle Cancer Center
Urbana, Illinois
Indiana University Health Hospital
Indianapolis, Indiana
Indiana University Health Melvin and Bren Simon Cancer Center
Indianapolis, Indiana
Showing 40 of 418 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.